Dr. Reddy’s Laboratories Ltd. Archives

Dr. Reddy’s Gets Positive CHMP Opinion for Rituximab Biosimilar

July 29, 2024 Mansi Praharaj Comments Off

Hyderabad India; July 29, 2024 – Dr. Reddy’s Laboratories Ltd., today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the launch of […]

Alvotech, Dr. Reddy’s Partner to Commercialize AVT03 Biosimilar in US, Europe, UK

May 22, 2024 Mansi Praharaj Comments Off

HYDERABAD, INDIA & REYKJAVIK, ICELAND (May 22, 2024) — Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories SA, wholly-owned subsidiary […]

Dr. Reddy’s Laboratories announces the launch of Febuxostat Tablets in the U.S. Market

January 12, 2021 Rekha Nair Comments Off

Hyderabad, India and Princeton, NJ, USA – Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as “Dr. Reddy’s” today announced the launch of Febuxostat Tablets, a therapeutic equivalent generic version of Uloric […]

Dr. Reddy’s confirms its voluntary nationwide recall of all Ranitidine products in the U.S. Market

Dr. Reddy’s and RDIF commence clinical trials for Sputnik V vaccine in India

December 1, 2020 Neel Achary Comments Off

Hyderabad: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), and Russian Direct Investment Fund (RDIF) announced today that they have commenced adaptive phase 2/3 clinical trials for Sputnik V vaccine in India after […]

Dr. Reddy’s announces the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, store-brand equivalent of Pepcid AC® in the U.S. Market

October 21, 2020 team Comments Off

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the re-launch of over-the-counter (OTC) Famotidine Tablets USP, 10 mg and 20 […]

Dr. Reddy’s Laboratories joins Science Based Targets initiative (SBTi) and sets 2030 GHG emission targets

October 6, 2020 team Comments Off

Hyderabad, India, October 5, 2020 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has joined the Science Based Targets initiative’s (SBTi) business ambition for 1.5°C, becoming the first Indian and the third […]

Dr. Reddy’s Laboratories announces the launch of Cinacalcet Tablets in the U.S. Market

October 3, 2020 team Comments Off

Hyderabad, India and Princeton, NJ, USA. October 2020 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of […]

Dr. Reddy’s announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. Market

September 26, 2020 team Comments Off

Hyderabad, India and Princeton, NJ, USA. September 25, 2020 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch […]

Dr. Reddy’s Laboratories announces the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-dose Syringe in the U.S. Market

September 8, 2020 team Comments Off

Hyderabad, India and Princeton, NJ, USA. September 7, 2020 – Dr Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch […]

Dr. Reddy’s Laboratories enters hospital nutrition segment with Celevida Maxx in India

August 26, 2020 team Comments Off

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DR REDDY, NYSE: RDY), today announced the entry into the hospital nutrition segment with the launch of its nutrition drink, ‘Celevida Maxx’ in India. It is a unique […]